&w=3840&q=100)
Canadian wildfire smoke chokes Midwest, sparks air quality concerns
Air quality alerts were in effect in Iowa, Minnesota, Wisconsin and Michigan, as well as eastern Nebraska and parts of Indiana and Illinois. Forecasters said the smoky skies would remain for much of the day.
Canadian environmental officials said smoke from the forest fires would persist into Sunday for some areas.
The Switzerland-based air quality monitoring database IQAir, which assesses air quality in real time, listed the city of Minneapolis as having some of the worst air pollution in the world since Friday. The Air Quality Index (AQI) was expected to reach the red or unhealthy category in a large swath of Minnesota.
AQI is a system used to communicate how much air pollution is in the air. It breaks pollution down into six categories and colours, along with advice on what is and is not safe to do. They range from good (the colour green) to hazardous (maroon).
People with lung disease, heart disease, children, older adults and pregnant women are most susceptible to the poor breathing conditions.
What's been unique in this go-around is that we've had this prolonged stretch of smoke particulates towards the surface, so that's where we've really had the air quality in the red here for the past few days, said Joe Strus, meteorologist with the National Weather Service in the MinneapolisSaint Paul area in Minnesota.
We've sort of been dealing with this, day in and day out, where you walk outside and you can taste the smoke, you can smell it, Strus said. Sometimes we've been in higher concentrations than others. Other times it's just looked a little hazy out there.
The air was improving Saturday, he said, specifically across the Twin Cities and southwestern Minnesota, but state health officials warned that conditions could remain unhealthy for sensitive groups through Monday.
Officials said the smoke could spread as far south as Tennessee and Missouri.
The EPA's Air Quality Index converts all pollutant levels into a single number. The lower the number, the better. Anything below 50 is classified as healthy. Fifty to 100 is moderate while 100-150 is unhealthy for sensitive groups. Anything above 150 is bad for everyone. Parts of Minnesota exceeded that number on Saturday.
Health officials advise people with asthma and other lung diseases, heart disease, children and older adults to avoid prolonged exposure to smoke and limit strenuous activities. They said to avoid burning things that could make the air pollution worse and to keep windows and doors closed.
This is something that's become part of our summer here the last few years, Strus said, and I think a lot of us are just looking forward to seeing a little more movement in the atmospheric winds and we'll be able to hopefully disperse some of the smoke out of here in the next few days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
an hour ago
- NDTV
Uttarakhand Floods Expose Gaps In Warning Systems, Expert Bats For AI Model
New Delhi: As the devastating flash floods in Uttarkashi claim lives and livelihoods yet again, experts flagged the failure to implement an integrated early warning system for the Himalayan region. The plan has been discussed for long and the experts warned that blaming climate change for such tragedies masks systemic governance failures. This, they say, is worsening the inherent vulnerabilities in areas like Uttarkashi and high-altitude villages such as Dharali. Calling for urgent action, they demand independent assessments to uncover the root causes of such tragedies and insist on accountability. Former Secretary of the Ministry of Earth Sciences Dr Rajeevan reflected on past efforts to address such vulnerabilities. "When I was the Secretary, we discussed an integrated early warning system for the whole Himalayan region. It was recorded in a high level meeting but it was not implemented," he said. "We need such a resilient system for the Himalayan region. The Ministry of Earth Sciences has recently launched the Mausam Mission. They should attempt to develop such early warning systems under that mission. The government has provided adequate funds to them. I understand the MoES will be taking up such initiatives. Yes, it should be implemented urgently. Otherwise, more damages can happen." Strengthening Early Warning Systems To improve Uttarakhand's Early Warning Systems for cloudburst-induced flash floods, experts advocate a multi-pronged approach leveraging advanced technology and community engagement. Dr Rajeevan emphasised upgrading observational infrastructure, including a dense network of X-band radars in upstream river catchments, more automatic weather stations, rain gauges, and river and stream gauging stations. "We need very high-resolution weather prediction models, about 1-3 km resolution," he said, acknowledging their limitations. "The accuracy of such physical models is not that good. Therefore, Artificial Intelligence-based algorithms should be considered," he added. He proposed developing AI-driven nowcasting systems that integrate satellite imagery, lightning data, and radar inputs to predict cloudburst events with a 1-3 hour lead time, coupled with mobile alert systems for rapid dissemination. Additionally, localized flash flood guidance systems using terrain-specific hydrological models and community-centric warning systems at the panchayat level were highlighted as critical. "Mobile and app-based alerts, along with terrain-specific hazard zoning and land-use policies, are essential to minimize risks," Dr Rajeevan added. Himanshu Thakkar of the South Asia Network on Dams, Rivers & People, echoed the need for technological advancements but stressed the importance of effective disaster management systems to act on early warnings. "This will be a combination of Doppler radars, satellite monitoring, river-based ground monitoring, and more intense monitoring in identified vulnerable locations," he said. "More importantly, we need a disaster management system that can use such advance information to remove people in time from vulnerable locations. We have a long way to go on this," he added. Mr Thakkar also called for robust governance mechanisms, including "honest, credible environment and social impact assessments of all major interventions, independent appraisals, confidence-inspiring monitoring, and compliance systems" to ensure accountability. "We are pretty poor in all these aspects," he noted. Unplanned Development Amplifies Disaster Impact The flash floods in Uttarkashi, particularly in areas like Dharali, were exacerbated by unplanned development, including the proliferation of hotels and homestays encroaching on river paths. Mr Thakkar highlighted the absence of policies to regulate such constructions. "We have no system to ensure that hotels, homestays, and other civil constructions are not encroaching on the path of rivers and streams. There is no system to remove such encroachments, and no assessment of the amount of space a river needs considering the current rainfall pattern and catchment health," he said. He pointed out that major projects like dams, hydropower plants, highways, railways, and urban centers contribute to environmental degradation by dumping muck into rivers, while schemes like riverfront developments and floodplain encroachments further constrict waterways. "The health of our catchments is degrading, which means rainfall is quickly converting into flow. That, combined with intensification of rainfall, means rivers need greater waterway, not smaller," Mr Thakkar explained. Dr Rajeevan also stressed the need for regulatory reforms, urging stricter controls on construction and tourism. "They are really spoiling the environment and river flow," he said, advocating terrain-specific hazard zoning and land-use policies to balance tourism with ecological safety. Integrated Flood Management for Resilience With cloudbursts becoming more frequent in Uttarakhand, potentially linked to climate change, experts underscore the need for integrated flood management strategies to enhance resilience, especially in high-altitude villages like Dharali. Mr Thakkar emphasized a combination of early warning systems, policies ensuring sufficient river waterways based on current and projected rainfall patterns, and robust monitoring and disaster management systems. "Most importantly, we need independent assessments that will provide information for accountability mechanisms," he said, advocating for post-disaster independent reviews to learn lessons and fix accountability. While acknowledging the role of climate change, Thakkar cautioned against using it as an excuse for poor governance. "The science of attribution is still being developed and today is not good enough to provide direct attribution. But climate change science tells us that in every such event of intensification of rainfall, there is a footprint of climate change," he said. "However, climate change should not be used as a carpet under which we can push all kinds of accountability and misgovernance. We know these events are increasingly likely, and we better be prepared for them rather than blaming it on climate change." Dr Rajeevan similarly called for proactive measures under the Mausam Mission, urging the Ministry of Earth Sciences to prioritise early warning systems. "The government has provided adequate funds. It should be implemented urgently," he reiterated.
Mint
an hour ago
- Mint
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
